{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-212606","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.520988+00:00","generated_at":"2026-05-31T06:23:57.712056+00:00","sec_items":["2.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Eiger sells lonafarnib ($5.2M) and peginterferon lambda ($1M) assets in Ch11; closings Sept 3","bullets":["Bankruptcy Court approved both asset sales on August 20, 2024; closings occurred September 3, 2024.","Lonafarnib antiviral assets sold to Eiger InnoTherapeutics for $5.2M plus cure costs and assumed liabilities.","Peginterferon lambda-1a assets sold to same buyer for $1.0M plus cure costs and assumed liabilities.","Company warns securityholders may face significant or total loss on investment given Chapter 11 outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-212606","json":"https://secwatch.observer/filing/0001193125-24-212606.json","markdown":"https://secwatch.observer/filing/0001193125-24-212606.md","text":"https://secwatch.observer/filing/0001193125-24-212606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/d889209d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:23:57.712056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb334e7d7d5911dc7968e0a02190274392b2d9a8","claim":"Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $5.2 million (closed 2024-09-03).","evidence_excerpt":"Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Eiger InnoTherapeutics, Inc."},{"label":"Consideration","value":"$5.2 million"},{"label":"Closing","value":"2024-09-03"}],"fact_type":"ma_transaction"},{"claim_id":"eb96a2743c21d5683940cae53c095bd4fad78928","claim":"Eiger BioPharmaceuticals, Inc. completed a disposition involving Eiger InnoTherapeutics, Inc. for $1.0 million (closed 2024-09-03).","evidence_excerpt":"Lonafarnib Antiviral Asset Sale On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the “ Purchaser ”) entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company’s rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Eiger InnoTherapeutics, Inc."},{"label":"Consideration","value":"$1.0 million"},{"label":"Closing","value":"2024-09-03"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}